+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1-beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers



The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1-beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers



Immunology 91(4): 548-552



Tumour necrosis factor-alpha (TNF-alpha) and interleukin-1-beta (IL-1-beta) are pro-inflammatory cytokines that play an important role in severe infections, whereas IL-1 receptor antagonist (IL-1ra) and IL-10 are anti-inflammatory cytokines that counteract their effects. Chlorpromazine and dexamethasone protect mice against lethal endotoxaemia by decreasing circulating concentrations of TNF-alpha and IL-1-beta. We investigated whether administration of chlorpromazine or dexamethasone to human volunteers is able to modulate the lipopolysaccharide (LPS)-stimulated cytokine production capacity in whole blood. Blood samples were taken before and several time-points after medication. Circulating cytokine concentrations were low in all samples. LPS-induced TNF-alpha and IL-1-beta production in whole blood was inhibited by dexamethasone treatment, while chlorpromazine had no effect. When peripheral blood mononuclear cells were stimulated in vitro with LPS, the addition of chlorpromazine (1-100 ng/ml) had no modulatory action on TNF-alpha, IL-1-beta, IL-1ra or IL-10 synthesis. The chlorpromazine concentrations measured in circulation of volunteers were eight to 40 times lower than the concentrations shown to be effective in mice. In conclusion, chlorpromazine inhibits TNF-alpha and IL-1-beta production in mice at concentrations that cannot be reached in humans, thus precluding its usage in clinical anti-cytokine strategies. In contrast, dexamethasone is an effective inhibitor of pro-inflammatory cytokine production.

(PDF emailed within 0-6 h: $19.90)

Accession: 009570372

Download citation: RISBibTeXText

PMID: 9378493

DOI: 10.1046/j.1365-2567.1997.00285.x


Related references

Human mesangial cells synthesize interleukin 1 alpha but not interleukin 1 beta, interleukin 1 receptor antagonist, or tumour necrosis factor. Nephrology, Dialysis, Transplantation 7(10): 997-1001, 1992

Immunoglobulin D enhances the release of tumour necrosis factor-alpha, and interleukin-1-beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology 88(3): 355-362, 1996

Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. British Journal of Haematology 109(1): 39-45, 2000

Polymorphisms in lymphotoxin alpha and interleukin-1 receptor antagonist genes and secretion of tumour necrosis factor alpha, soluble interleukin-2 receptor and interleukin 6 in Chinese patients with inflammatory bowel disease. Gastroenterology 114(4 PART 2): A1117, April 15, 1998

Relation of polymorphism of lymphotoxin alpha and interleukin 1 receptor antagonist genes to secretion of tumour necrosis factor alpha, soluble interleukin 2 receptor and interleukin 6 in Chinese patients with inflammatory bowel disease. Acta Academiae Medicinae Hubei 18(3): 209-213, 1997

Cytokines and malaria. Study of tumour necrosis factor alpha, interleukin 1 beta, interleukin 6 and of the soluble interleukin 2 receptor in 28 patients. Bulletin de la Societe de Pathologie Exotique 87(2): 91-96, 1994

Interleukin 1 alpha induced interleukin 1 beta and tumor necrosis factor alpha and inhibition by interleukin 1 receptor antagonist. American Review of Respiratory Disease 145(4 PART 2): A270, 1992

Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6, (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas. European Journal of Cancer 33(13): 2246-2251, 1998

Involvement of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-8, and interleukin-1 receptor antagonist in acute lung injury caused by local Shwartzman reaction. Pathology International 47(1): 16-24, 1997

Detection of intracytoplasmic interleukin-1 alpha, interleukin-1 beta, interleukin-6 and tumour necrosis factor alpha expression in human monocytes using two-colour immunofluorescence flow cytometry. International Journal of Experimental Pathology 73(5): A15, 1992

Cellulose acetate beads induce release of interleukin-1 receptor antagonist, but not tumour necrosis factor-alpha or interleukin-1beta in human peripheral blood. Inflammation Research 52(7): 287-290, 2003

Lipopolysaccharide from Actinobacillus actinomycetemcomitans stimulates production of interleukin-1beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-1 receptor antagonist in human whole blood. Journal of Periodontal Research 34(1): 34-40, 1999

Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 99(3): 276-284, 2005

Human macrophage responses to vaccine strains of influenza virus: synthesis of viral proteins, interleukin-1 beta, interleukin-6, tumour necrosis factor-alpha and interleukin-1 inhibitor. Vaccine 11(1): 36-42, 1993

Activation of human natural killer cells by lipopolysaccharide and generation of interleukin 1 alpha beta tumor necrosis factor and interleukin 6 effect of il 1 receptor antagonist. Immunology 73(4): 450-456, 1991